Matt Truppo
About Matt Truppo
Matt Truppo is the Head of Global Research Platforms, focusing on integrating advanced technologies like mRNA and AI in research and development.
Title: Head of Global Research Platforms
Matt Truppo holds the title of Head of Global Research Platforms. In this role, he focuses on integrating advanced technology platforms such as mRNA and artificial intelligence into research and development initiatives. His responsibilities include overseeing the development and implementation of cutting-edge research strategies aimed at driving innovation in the biotech field.
Partnerships with Leading-Edge Data Science Companies
Matt Truppo actively engages in strategic partnerships with leading-edge data science companies like Owkin and Exscientia. These collaborations leverage AI platforms to enhance research capabilities and drive forward the development of new therapies. These partnerships aim to harness the power of data and machine learning to expedite the discovery and optimization of novel treatments.
Utilization of Advanced Molecules and Technologies
In his capacity, Truppo utilizes sophisticated technologies such as SYNTHORIN™ molecules for the design and optimization of protein-based treatments. He also develops monoclonal antibodies for rapid defense against certain diseases. Furthermore, his work involves using inactivated, live-attenuated, polysaccharide-based, recombinant protein, and conjugated-polysaccharide vaccines.
Collaborations for Innovative Therapeutic Development
Matt Truppo collaborates with Alnylam to harness RNA interference in creating new therapies for rare blood disorders. Additional collaborations include partnerships with Kymera and Nurix to develop advanced protein degrader therapies. These efforts are aimed at pushing the boundaries of therapeutic development and addressing complex medical conditions.
Innovative Immunotherapy Solutions
Under Truppo's leadership, the development of proprietary “masking” technology is advancing immunotherapies that overcome challenges associated with T-cell engagers. His work also involves exclusive access to IGM Bio’s immunology platform for creating a new class of antibodies, and the development of multi-specific antibodies targeting two or three different markers to address cancers and immunological disorders.